NY-ESO-1b
DRACPC ID DRACPC0104
Active Ingredients NY-ESO-1b
Description A recombinant nonapeptide used as an antineoplastic vaccine. NY-ESO-1b peptide vaccine contains the amino acid sequence SLLMWITQC, derived from the cancer-testis tumor antigen (NY-ESO-1), which is expressed on tumor cells of many different types, including melanomas. Vaccination with this peptide vaccine may elicit strong humoral and cellular immune responses to NY-ESO-1-expressing cancers.
Synonyms NY-ESO-1b Peptide (p157-165); NY-ESO-1b Peptide Vaccine; NY-ESO-1b
Type Biotech
Disease Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula Not available
Molecular Weight Not available
Active Sequence SLLMWITQC
Sequence Length 9
Modification Not available
Structure
IUPAC Name Not available
InChI Not available
InChI_Key Not available
SMILES Not available
External Codes
PubChem CID Not available
DrugBank Accession Number Not available
NCI Thesaurus Code C68999
UNII Not available
CAS Not available
Drug approval
Drug indication
Investigated for use/treatment in Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00066729 | A Phase I Study Of NY-ESO-1b Peptide Plus Montanide ® ISA-51 In Patients With Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer | Phase 1 | Treatment |
| NCT00199836 | A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer Expressing NY-ESO-1 or LAGE-1. | Cancer; Neoplasm | Phase 1 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
